Sandoz TV Episode 18: Trailer
Find out what to expect from the newest episode of Sandoz TV.
|Global News||Sandoz Around the World||Sandoz in the Media|
Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014; portfolio transformation will focus company on leading businesses
Basel, January 27, 2015
Novartis delivered solid sales growth, margin expansion and pipeline progress in 2014
Sandoz biosimilar filgrastim recommended for approval by FDA Oncologic Drugs Advisory Committee
Holzkirchen, January 07, 2015
Sandoz, a Novartis company, announced today that US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of its biosimilar filgrastim in the US.
Sandoz launches authorized generic version of Vivelle-Dot®
Princeton, New Jersey, December 22, 2014
Sandoz today announced the US market introduction of estradiol transdermal system, an authorized generic version of Vivelle-Dot®, which is marketed by Novartis Pharmaceuticals Corporation.
Sandoz Brazil launches Tadalafil, first generic version of Cialis® to treat erectile dysfunction
Sao Paulo, December 18, 2014
Sandoz, the generics pharmaceutical division of Novartis, announces today that it is launching Tadalafil, a generic version of Cialis®, indicated to treat patients with erectile dysfunction.
Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN®
Holzkirchen, December 08, 2014
Sandoz, a Novartis company, announced today Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen’s NEUPOGEN®